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Abstract
Objective
To assess the methodological quality of published network meta-analysis.
Design
Systematic review.
Methods
We searched the medical literature for network meta-analyses of pharmaceuticals. We assessed general study characteristics, 
study transparency and reproducibility, methodological approach, and reporting of findings. We compared studies published in 
journals with lower impact factors with those published in journals with higher impact factors, studies published prior to January 1 , 
2013 with those published after that date, and studies supported financially by industry with those supported by non-profit 
institutions or that received no support.
Results
The systematic literature search identified 854 citations. Three hundred and eighteen studies met our inclusion criteria. The number 
of network meta-analyses has grown rapidly, with 48% of studies published since January 2013. The majority of network meta-
analyses were supported by a non-profit institution or received no support (68%). We found considerable inconsistencies among 
reviewed studies. Eighty percent reported search terms, 61% a network diagram, 65% sufficient data to replicate the analysis, and 
90% the characteristics of included trials. Seventy percent performed a risk of bias assessment of included trials, 40% an 
assessment of model fit, and 56% a sensitivity analysis. Among studies with a closed loop, 69% examined the consistency of direct 
and indirect evidence. Sixty-four percent of studies presented the full matrix of head-to-head treatment comparisons. For Bayesian 
studies, 41% reported the probability that each treatment was best, 31% reported treatment ranking, and 16% included the model 
code or referenced publicly-available code. Network meta-analyses published in higher impact factors journals and those that did 
not receive industry support performed better across the assessment criteria. We found few differences between older and newer 
studies.
Conclusions
There is substantial variation in the network meta-analysis literature. Consensus among guidelines is needed improve the 
methodological quality, transparency, and consistency of study conduct and reporting.
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Introduction
Network meta-analysis (NMA) is increasingly accepted as a valuable methodology by clinical researchers and health care decision 
makers.[1–3] Network meta-analysis has been described as the “new generation” of evidence synthesis and the number of 
published studies is growing rapidly.[4] The approach has been embraced by national health technology assessment agencies in a 
number of countries, including Australia, Canada, and the UK.[5–7] The Cochrane Collaboration has also introduced a new type of 
review called ‘Overviews of Reviews’, which summarize the relative effectiveness of multiple competing interventions for a single 
indication.[8,9] A report by the Agency for Healthcare Research and Quality in the US identified 25 publicly-available guidance 
documents on how to conduct and report network meta-analyses.[10] National and regional health technology assessment 
agencies prepared the majority of these documents, although the guidance issued by the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) was considered to be most comprehensive.[10]
The objective of this study was to assess the methodological quality of published NMAs. Previous studies have documented the 
growth and study characteristics of the NMA literature through July 2012.[3,4,11–14] These reviews investigated the validity 
assumptions and methods of using NMAs. Our study builds on this body of literature in several ways. First, we update the evidence 
by including articles published up to July 2014. Second, we investigate the methods, the transparency and reproducibility, and the 
presentation of findings in these studies. Finally, we compare the characteristics of studies published in journals with lower impact 
factors with those published in journals with higher impact factors, studies published prior to January 1 , 2013 with those published 
after that date, and studies supported financially by industry with those supported by non-profit or that received no support.
Methods
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We systematically searched for all published network meta-analyses in the Ovid-MEDLINE database using the following search 
terms: network meta-analysis; indirect treatment comparison; mixed treatment comparison; and, multiple treatments meta-analysis. 
The date of our last search was July 30 , 2014. We limited our search to studies including randomized controlled trials with human 
participants; we only included articles published in English-language journals. We excluded NMAs submitted to national health 
technology assessment agencies unless they were subsequently published in the medical literature.
Two trained reviewers reviewed each abstract independently using predefined inclusion criteria. We only included NMAs with at 
least one pharmaceutical in the set of treatments examined and data from at least three clinical trials; we also only included NMAs 
that compared the efficacy of the treatments. We excluded methodological studies, cost-effectiveness studies, editorials, and letters 
to the editor. Two trained reviewers independently extracted data from each included study; the reviewers resolved disagreements 
through consensus. We reviewed all published material related to each NMA, including the online supplementary material and 
appendices. When the source of study funding was undeclared or unclear, we contacted the corresponding author for the 
information.
Using a standardized data collection form, we collected information for each NMA on general study characteristics, study methods, 
transparency, and presentation of findings. We reported the following study characteristics: journal name; study authors; publication 
year; study support (industry or other); journal impact factor (as reported on Journal Citation Reports)[15]; country (determined by 
the corresponding author’s affiliation); number of included active treatments; number of clinical trials included; total number of 
patients included; and indication and patient population studied. We also noted all of the comparator treatments, including non-
pharmaceutical treatments and different modes of administration of the same pharmaceutical.
We applied objective assessment criteria from the “checklist of good research practices” in the ISPOR guidance for interpreting and 
conducting indirect-treatment-comparison and network-meta-analysis studies.[16,17] Our assessment criteria included the 
following: 
Study method assessment criteria 
Study transparency and reproducibility assessment criteria 
Presentation of study findings 
To compare studies published in high- and low-impact journals, we evenly split the sample based on the reported journal impact 
factors (cut-off point: impact factor above and below 3.534). To compare older and newer studies, we again divided the sample in 
two (cut-off point: published before and after January 1 , 2013). We used our categorization of study support to compare industry-
supported studies with studies with and non-industry-supported studies. We used a Chi-square test and a student’s t-test to 
evaluate categorical and continuous variables, respectively. We considered p-values below the 5% level as statistically significant. 
Analyses were undertaken using Stata 13.
Results
Our systematic literature search identified 854 citations. We reviewed the full texts of 386 abstracts met the inclusion criteria. Based 
on the full text reviews, we excluded another 68 studies. We included 318 studies in our final sample (Fig 1).
Fig 1. Identification of network meta-analyses included in review.
doi:10.1371/journal.pone.0121715.g001
Table 1 presents the frequency of published NMAs by year, indication, and country; it also presents the types of included 
pharmaceutical included. The number of NMAs has increased rapidly each year; about 68% and 48% of studies were published 
after January 2012 and January 2013, respectively. Studies have evaluated treatments for a range of indications, most commonly 
those affecting the circulatory (n = 64, 20%) and musculoskeletal systems (n = 45, 14%). Analyses were most often performed by 
researchers based in the USA (n = 81, 26%), UK (n = 79, 25%), and Canada (n = 28, 9%). The majority of studies adopted a 
Bayesian framework (n = 214, 67%) and either received non-profit or no support (n = 215, 68%).
th
Was a Bayesian or a frequentist framework used?

Was the risk of bias of included clinical trials assessed? (e.g., using the Cochrane Collaboration's tool for assessing risk of bias or the Jadad scale?) 
[18,19]

Did the analysis include adjustments for model covariates?

Was a fixed or random effects model used? Or, were the findings of both fixed and random effects models presented?

Was an assessment of model fit reported?

Was a sensitivity analysis performed? (e.g., varied the included clinical studies to evaluate the robustness of the findings)

For studies with at least one closed loop, was the consistency of direct evidence and indirect evidence evaluated? (i.e., presented and compared the 
findings from the traditional meta-analysis and the network meta-analysis)

Were the search terms reported?

Was a network diagram of included treatments presented?

Was data from the included clinical studies necessary to reproduce the network meta-analysis presented?

Was a table of key clinical study characteristics presented?

Was the model code presented or source cited? (reported for studies performed using a Bayesian framework only)

Were pairwise comparisons of all included treatments presented?

Was the probability of each treatment being best reported? (reported for studies performed using a Bayesian framework only)

Was a ranking of treatments in terms of effectiveness reported? (reported for studies performed using a Bayesian framework only)

st
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Table 1. Frequency of network meta-analyses (n = 210) by year, indication, and country.
doi:10.1371/journal.pone.0121715.t001
The vast majority of network meta-analyses compared multiple pharmaceuticals (n = 304, 96%), while a minority included a non-
pharmaceutical comparator treatment (n = 30, 9%). Some researchers grouped treatments in the same therapeutic class, e.g., 
beta-blockers or statins, as a single comparator treatment (n = 75, 24%). Different dosages, e.g., simvastatin 20 mg vs. 40 mg, 
were compared in 82 (26%) studies, and ten studies (3%) compared different modes of administration of the same pharmaceutical, 
e.g., oral vs. intramuscular injection.
We found many differences among the included studies (Table 2). In terms of study methods, 30% of studies did not perform a risk 
of bias assessment of included studies, 60% did not report an assessment of model fit, and 44% did not include a sensitivity 
analysis. Among studies with a closed loop, i.e., three or more included treatments had been compared in head-to-head trials, 40% 
did not report the consistency of direct and indirect evidence. In terms of study transparency and reproducibility, 20% did not report 
the systematic review search terms, 39% did not present a network diagram, 35% did not present sufficient data from contributing 
studies to replicate the analysis, and 10% did not provide details of the key characteristics of included trials. Thirty-six percent of 
included studies did not present the full matrix of head-to-head treatment comparisons. For studies performed using a Bayesian 
framework, 41% reported the probability that each included treatment was best, 31% reported a ranking of included treatments, and 
16% included or directed readers to the model code.
Table 2. Assessment of network meta-analysis study characteristics.
doi:10.1371/journal.pone.0121715.t002
Journal quality
Page 3 of 6PLOS ONE: An Assessment of the Methodological Quality of Published Network Me...
13/05/2015http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0121715
We found that NMAs published in journals with higher impact factors more often performed a sensitivity analysis (62% versus 50%, 
p = 0.0267) and reported the full matrix of head-to-head comparisons (70% versus 57%, p = 0.0191). For studies with a closed 
loop, those published in journals with higher impact factors more often compared the consistency of direct and indirect evidence 
(79% versus 57%, p = 0.0017). For studies performed using a Bayesian framework, studies published in higher impact factor 
journals more often reported the probability of each treatment being best (33% versus 22%, p = 0.0277), and the model code (16% 
versus 6%, p = 0.0085).
Publication date
We found that studies published prior to January 1 , 2013 were more often authored by researchers based in regions where HTA 
agencies include NMAs in their assessments (47% versus 28%, p = 0.0156). Studies published prior to January 1 , 2013 less often 
performed a risk of bias assessment of included trials (62% versus 79%, p = 0.005), but, for Bayesian studies, more often reported 
the model code or cited publicly-available code (14% versus 7%, p = 0.0439).
Source of financial support
We found a number of differences between industry-supported studies and non-industry supported studies. Industry-supported 
studies included fewer trials (22.7 versus 37.4, p = 0.0079) and a smaller total number of patients (10945 versus 33864, p = 
0.0050). A greater proportion of industry-funded studies were authored by researchers based in regions in which HTA agencies 
often include NMA in their assessments (49% versus 28%, p = 0.0079). Industry-supported studies were on average published in 
journals with lower impact factors (3.1 versus 6.5, p<0.0001).
Industry-supported studies more often used a Bayesian framework (77% versus 63%, p = 0.0191), and adjusted for study 
covariates (38% versus 25%, p = 0.0251); however, they less often performed a risk of bias assessment of included studies (54% 
versus 77%, p<0.0001), and, for Bayesian studies, less often compared the consistency of direct and indirect evidence (39% 
versus 79%, p<0.0001).
Industry-supported studies less often reported the search terms used in the systematic literature review (62% versus 88%, 
p<0.0001), and reported the full matrix of head-to-head comparisons (45% versus 73%, p<0.0001). For studies performed using a 
Bayesian framework, industry-supported studies less often reported a ranking of treatments (11% versus 26%, p = 0.0031).
Discussion
Network meta-analyses are increasingly recognized as offering valuable information to the medical community. Growth in the NMA 
literature has been rapid, with roughly half of studies in our dataset published since January 1 , 2013. Our dataset includes studies 
by researchers based in 30 countries, confirming NMAs as a global research enterprise. We found notable variation across 
published network meta-analyses with respect to methods, transparency and reproducibility, and presentation of findings.
As expected, we found that studies published in higher-impact journals performed better across our assessment criteria, suggesting 
that higher-quality journals publish higher quality NMAs. Our findings may also point to a marginal improvement in the conduct and 
reporting of NMAs over time, with more recently published studies more often performing a risk of bias assessment of included 
trials. Interestingly, more recent Bayesian studies less often reported the model code, perhaps reflecting the fact that example 
model code has become easily accessible and freely available.[20] It is notable that a smaller proportion of studies are now 
authored by researchers based in regions where HTA agencies include network meta-analysis in their assessments. This likely 
reflects the widespread acceptance of NMA and the growing international use of the technique by researchers.
We also found differences among NMAs according to source of financial support. For instance, we found that industry-supported 
studies tended to be published in journals with a lower impact factor. Similarly, industry-supported studies were more often 
authored by researchers based in HTA regions, which is likely due to the publication of NMAs that were previously included in a 
submission to a regulatory agency. An interesting finding is that industry-sponsored studies less often used a Bayesian framework, 
the reason for which is unclear.
Consistent with the studies published in journals with higher impact factors, we found that industry-supported studies less often 
reported the full matrix of head-to-head comparisons. For NMAs with a closed loop, they less often compared the consistency of 
direct and indirect evidence. Like older analyses, industry-supported studies were less likely to perform a risk of bias assessment of 
included trials.
Other identified differences between industry-supported and non-industry-supported studies do not appear to be explained by 
journal quality or the data of publication. For instance, industry-supported studies included fewer contributing trials and total 
patients, and less often reported the systematic review search terms. Industry sponsored Bayesian network meta-analyses less 
often reported a ranking of included drugs based on efficacy, although they more often adjusted for covariates. However, as we 
emphasize below, these findings should be interpreted with caution due to limitations of our assessment criteria.
Study limitations
While our assessment criteria were based on published guidelines for the conduct and reporting of network meta-analysis, they 
may have been insufficient to fully assess study quality. For example, while we determined whether a study reported a sensitivity 
analysis or assessed the model fit, we did not judge whether the approaches were appropriate or sufficient. We also did not 
evaluate whether the set of included treatments was appropriate or comprehensive. This is a salient consideration as the 
inappropriate inclusion or exclusion of treatments can significantly affect study findings.
Furthermore, a study may have not met an assessment criterion, or appear to have performed poorly on a given criterion, for good 
reason. For instance, while industry-supported studies included fewer contributing studies and total patients, this may reflect the 
precision of the study research question, rather than the how comprehensively the question was addressed. Similarly, while 
guidelines recommend assessing included trials for risk of bias, the influence of individual design components of individual 
randomized trials on the findings is variable. [21–23] While it is recommended that the consistency between direct and indirect 
evidence should be assessed, researchers may be more inclined to do so when there is apparent heterogeneity among the 
included trials.[24–28]
For indications for which the relative efficacy of existing treatments has been established by multiple NMAs, a researcher may 
choose to compare a newly-introduced treatment to existing interventions, rather than to report the full matrix. Moreover, it is 
reported that treatment rankings may at times be an unreliable metric for comparative efficacy and safety, and authors may choose 
not to present these findings.[29]
Our comparison of NMAs on the basis of study support has a number of additional limitations. First, while we took great care when 
categorizing studies as ‘industry-supported’ and contacted authors when source of support was ambiguous, we predominantly 
relied on the reported disclosures. Second, we did not compare the conclusions of industry-and non-industry-supported NMAs. To 
determine if industry-supported studies tend to produce more favourable conclusions about the study sponsors’ drugs, it would be 
necessary to identify and compare industry sponsored and non-industry sponsored trials that evaluate the same clinical research 
questions.[30,31] Unfortunately, while various NMAs have been conducted for some indications, these studies often considered 
different research questions and included different treatments. This prevented us from evaluating the NMA literature in this way.
Moving forward
This research highlights the need for greater consistency in the conduct and reporting of NMAs. In addition to the ISPOR 
recommendations used here, there exist a multitude of guidelines and recommendations with notable differences. This suggests 
that a consensus, on which NMA methods are most appropriate has not been reached.[10] [32] While the development of 
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guidelines advances the field, inconsistencies between guidelines may impede standardization. For example, while all guidelines 
are unanimous in stating the consistency between direct and indirect evidence should be assessed, there is disagreement with 
respect to the importance of testing model fit, the use of fixed- or random-effects models, and the exclusion or inclusion of 
covariates in the model.[10]
As NMAs are an extension of traditional meta-analyses, it seems logical that they should be held to similar methodological and 
reporting standards. For systematic reviews and traditional meta-analysis, the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) protocol—which consists of a 27-item checklist and a four-phase flow diagram—has emerged as the 
standard reporting approach.[33] The forthcoming extension of the PRISMA guidelines for network meta-analysis may consolidate 
existing recommendations, and serve as the authoritative guideline.
Still, our study underscores that checklists should be considered only as guides to study quality. A NMA that satisfies all criteria on 
a given checklist may not necessarily be a high-quality study, and a study that does not meet various criteria may not necessarily 
be a low-quality study. Indeed, the recent ISPOR-AMCP-NPC Good Practice Task Force Report is a questionnaire, not a checklist, 
reflecting the challenge of creating a ‘one size fits all’ checklist for network meta-analyses.[34] It is important that users of network 
meta-analyses critique the research, and make their own judgment regarding study quality and accuracy. Journal editors should 
ensure that published network meta-analyses are transparent and reproducible, and that these studies present findings in an 
unambiguous and comprehensive manner.
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